How can Europe build a clinical trials ecosystem that delivers for patients and innovation?
A joint statement from the EU Health Coalition
Clinical trials are essential to delivering new and improved treatment options for patients. Yet Europe's share of global clinical research has almost halved in a decade. The EU Health Coalition calls on European decision-makers to seize this moment and build a clinical trials ecosystem that delivers for patients and innovation.
Europe is under growing pressure to strengthen its position in global health innovation. As the US and China continue to advance their life sciences capabilities, closing Europe's innovation gap has become a priority on the EU agenda. Central to that effort is ensuring Europe's scientific excellence translates into innovation, investment and, above all, benefits for patients.
Clinical research sits at the heart of this challenge. Clinical trials generate the evidence needed to develop new medicines and health technologies and bring them to patients. They give patients access to promising new treatments, support clinicians and researchers, and provide an important foundation for research, innovation and investment in Europe. When trials move elsewhere, European patients, health systems and economies all lose out.
Europe is losing ground
Europe's position as a destination for clinical research has weakened in recent years. Despite a 38% increase in global commercial clinical trials between 2013 and 2023, the share for the European Economic Area (EEA) fell from 22% to 12% over the same period. This has been estimated to correspond to around 60,000 fewer clinical trial places for European patients.[1] Moreover, non-commercial clinical trial starts in the EEA declined by 11% in paediatric research and 12% in rare diseases between 2018 and 2023.[2]
These figures point to broader, systemic challenges across Europe's clinical research ecosystem. Regulatory and administrative complexity, fragmentation across Member States and difficulties in running multinational trials all make Europe a harder place to conduct research. Challenges in patient recruitment, funding and research capacity add further pressure. However, new legislation now presents an opportunity to build on the existing framework and create a more efficient environment for clinical research.
Seizing the opportunity of the Biotech Act and European Health Data Space (EHDS)
The proposed European Biotech Act I is an important opportunity to change course. Alongside wider measures to strengthen Europe's biotechnology and biomanufacturing ecosystem, it proposes targeted changes to the Clinical Trials Regulation (CTR). This brings clinical research firmly into the EU's competitiveness and innovation agenda. It also builds on the Accelerating Clinical Trials in the EU (ACT EU) initiative, launched in 2022 by the European Commission, the European Medicines Agency and the Heads of Medicines Agencies.
Similarly, the European Health Data Space (EHDS) provides the opportunity for creating the infrastructure foundation so quality health data can be re-used and shared for clinical research efficiently across all member states.
The question now is whether these changes will be enough to make Europe a more efficient and attractive place for clinical research: one that works for patients, researchers, clinicians and innovators alike. Regulatory reform is a necessary first step, but it must be matched by action. The EU Health Coalition calls on EU institutions and Member States to:
- Streamline regulatory and administrative complexity. Ensure the revised CTR delivers faster, simpler and more predictable processes for sponsors, investigators and patients.
- Strengthen co-ordination across borders. Smoother collaboration and enhanced trust are needed between Member States, including on ethics review and national implementation, so that running a trial across several countries becomes the norm rather than the exception.
- Support commercial and non-commercial research alike. Recognise the distinct needs of academic and investigator-led trials. Secure the funding and incentives needed in underserved areas, such as paediatrics and rare diseases, where small patient populations and limited commercial incentives make clinical trials more difficult to initiate and conduct.
- Put patients at the centre. Involve patients in how trials are designed and run, at different governance levels, and make it easier for patients across Europe to find and take part in clinical research. This is particularly important for those affected by rare diseases and conditions for which research opportunities and current availability of treatments remain limited.
- Invest in research capacity and data. Build the infrastructure, skills and networks Europe needs to conduct clinical trials and invest on the already-existing infrastructures and capacities, including hospitals and biobanks. Strengthen patient registries, access to high-quality biological samples and related data, support the validation and use of biomarkers, and expand the use of digital tools in clinical research. These investments are particularly important for trials involving small or geographically dispersed patient populations, where collaboration and data sharing across centres and countries can help address recruitment challenges and strengthen the clinical evidence base.
- Harness real-world data. Routinely collected health data can inform study design and feasibility and help identify participants, enabling faster, more representative recruitment. Transferring data securely from electronic health records into trial systems (EHR-to-EDC) can reduce duplicate data entry and site workload, while follow-up through health records and well-designed observational studies can generate evidence on longer-term outcomes in routine care. Building on the European Health Data Space, EU institutions and Member States should enable these uses through interoperable infrastructure, proportionate governance and clear data-quality requirements, while protecting patients’ rights and maintaining scientific rigour.
- Focus on implementation. Ensure new rules establish feasible objectives, applied consistently across Member States. Track progress so that reforms deliver real change on the ground.
Working together for patients
No single actor can fix Europe's clinical trials ecosystem alone. Patients, healthcare professionals, researchers, academia and industry each bring a vital perspective. As a collective that brings these voices together, the EU Health Coalition believes that progress depends on collaboration across the whole clinical research ecosystem. We urge decision-makers to treat the Biotech Act and the revision of the CTR as a starting point, not an end.
Together, we can make Europe an attractive place for clinical research once again. The EU Health Coalition stands ready to work with EU institutions and Member States to build a clinical trials ecosystem that truly delivers for patients and innovation.
About the EU Health Coalition
The EU Health Coalition was created in November 2018, following the first-ever EU Health Summit. The Coalition promotes a shared vision of health in Europe, based on jointly developed recommendations. The purpose is to ensure that health remains high on the political agenda and to champion the changes required to address the unprecedented challenges that an ageing population and an increasing prevalence of chronic diseases pose to healthcare systems and citizens.
The EU Health Coalition is composed of 57 patient organisations, EU research-oriented medical societies, industry organisations, healthcare providers, regional and local health authorities and other relevant stakeholders, who all share a common vision.
References: